Valuation: China Resources Double-Crane Pharmaceutical Co.,Ltd.

Market Cap 16.79B 2.51B 2.24B 2.07B 1.88B 3.53B 238B 3.59B 24.89B 9.78B 125B 9.43B 9.23B 398B P/E 2026 *
9.51x
P/E 2027 * 8.89x
Enterprise Value 16.79B 2.51B 2.24B 2.07B 1.88B 3.53B 238B 3.59B 24.89B 9.78B 125B 9.43B 9.23B 398B EV / Sales 2026 *
1.47x
EV / Sales 2027 * 1.4x
Free-Float
37.31%
Yield 2026 *
3.14%
Yield 2027 * 3.26%
1 day-1.09%
1 week-0.12%
Current month+0.12%
1 month+2.46%
3 months-6.01%
6 months-10.56%
Current year-11.10%
1 week 16.15
Extreme 16.15
16.66
1 month 15.86
Extreme 15.86
16.66
Current year 15.29
Extreme 15.29
19.08
1 year 15.29
Extreme 15.29
19.77
3 years 14.8
Extreme 14.8
26.15
5 years 11.25
Extreme 11.25
37.44
10 years 10.66
Extreme 10.66
37.44
Manager TitleAgeSince
Director of Finance/CFO 43 2025-02-17
President 45 2024-10-24
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 68 2006-05-29
Director/Board Member 67 2021-07-11
Director/Board Member 60 2022-10-09
Date Insider Type Main position Quantity % Market Cap. Importance
12/21/22 Buy

Chairman

5,000 0.0005%
12/21/22 Buy

Director

10,000 0.0010%
12/20/22 Buy

Director

5,000 0.0005%
Change 5-day change 1-year change 3-year change Capi.($)
-1.09%-0.12%-13.74%+6.90% 2.54B
+3.49%+10.04%+58.68%+119.56% 1,106B
+2.19%+4.32%+33.88%+69.52% 612B
+2.26%+5.37%+24.57%+97.69% 500B
+2.58%+8.37%+38.71%+63.14% 367B
+3.25%+4.45%+71.80%+44.44% 354B
+1.85%+6.04%+21.47%+49.17% 286B
+1.76%+6.07%+0.43%+20.98% 256B
+3.29%+6.32%+44.71%+57.43% 230B
+2.25%+5.81%+27.13%+101.17% 190B
Average +1.73%+3.62%+30.76%+63.00% 390.27B
Weighted average by Cap. +1.43%+4.66%+40.79%+80.53%

Financials

2026 *2027 *
Net sales 11.39B 1.71B 1.52B 1.41B 1.27B 2.4B 162B 2.44B 16.88B 6.63B 84.55B 6.4B 6.26B 270B 11.98B 1.79B 1.6B 1.48B 1.34B 2.52B 170B 2.56B 17.75B 6.97B 88.89B 6.73B 6.59B 284B
Net income 1.78B 266M 237M 219M 199M 374M 25.19B 380M 2.63B 1.03B 13.18B 997M 977M 42.05B 1.9B 284M 253M 235M 213M 400M 26.95B 406M 2.82B 1.11B 14.1B 1.07B 1.04B 44.98B
Net Debt - -
Projected Income Statement - Annual - China Resources Double-Crane Pharmaceutical Co.,Ltd.
Logo China Resources Double-Crane Pharmaceutical Co.,Ltd.
China Resources Double-Crane Pharmaceutical Co Ltd is a China-based company primarily engaged in the new drug research and development, preparation production, drug sales, and active pharmaceutical ingredients (API) production. The Company operates two segments. The Infusion segment is mainly engaged in the production and sale of infusion products and the provision of services. The Non-Infusion segment is mainly engaged in the production and sale of non-infusion products and the provision of services. The Company's chronic disease business products include compound reserpine triamterene tablets, gliquidone tablets and others. The Company's specialty business products include teniposide injection, busulfan injection and others. The Company's infusion business products include basic infusion, therapeutic infusion, nutritional infusion and other multi-category infusion products. The Company's API business products include valsartan, amlodipine, pregabalin and others.
Employees
13,184
Date Price Change Volume
26-10-20 CN¥16.26 -1.09% 8,061,100
26-10-19 CN¥16.44 +0.43% 5,657,500
26-10-16 CN¥16.37 +0.18% 8,305,200
26-10-15 CN¥16.34 -1.03% 7,954,135
26-10-14 CN¥16.51 +1.41% 8,945,833
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - China Resources Double-Crane Pharmaceutical Co.,Ltd.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
16.26CNY
Average target price
24.30CNY
Spread / Average Target
+49.45%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - China Resources Double-Crane Pharmaceutical Co.,Ltd.
  1. Stock Market
  2. Stocks
  3. 600062 Stock